Citadel Advisors
ZVRA icon

Citadel Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Citadel Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Buy
243,400
+86,200
+55% +$777K ﹤0.01% 5819
2025
Q4 		$1.41M Buy
157,200
+55,100
+54% +$521K ﹤0.01% 6645
2025
Q3 		$971K Buy
102,100
+33,200
+48% +$333K ﹤0.01% 7590
2025
Q2 		$607K Sell
68,900
-23,900
-26% -$194K ﹤0.01% 8172
2025
Q1 		$695K Buy
92,800
+8,700
+10% +$69.1K ﹤0.01% 7766
2024
Q4 		$701K Sell
84,100
-49,400
-37% -$422K ﹤0.01% 7825
2024
Q3 		$926K Buy
133,500
+113,500
+568% +$770K ﹤0.01% 7023
2024
Q2 		$98K Sell
20,000
-8,765
-30% -$41.5K ﹤0.01% 10942
2024
Q1 		$167K Sell
28,765
-56,400
-66% -$347K ﹤0.01% 10603
2023
Q4 		$558K Buy
85,165
+18,865
+28% +$88.2K ﹤0.01% 7862
2023
Q3 		$320K Sell
66,300
-18,400
-22% -$91.9K ﹤0.01% 9048
2023
Q2 		$432K Sell
84,700
-20,300
-19% -$109K ﹤0.01% 8259
2023
Q1 		$578K Sell
105,000
-138,300
-57% -$732K ﹤0.01% 8023
2022
Q4 		$1.12M Sell
243,300
-23,300
-9% -$118K ﹤0.01% 6600
2022
Q3 		$1.66M Buy
266,600
+19,300
+8% +$109K ﹤0.01% 5943
2022
Q2 		$1.1M Sell
247,300
-86,400
-26% -$394K ﹤0.01% 6804
2022
Q1 		$1.68M Buy
333,700
+83,900
+34% +$534K ﹤0.01% 6484
2021
Q4 		$2.18M Buy
249,800
+66,800
+37% +$596K ﹤0.01% 6038
2021
Q3 		$1.71M Buy
183,000
+30,000
+20% +$302K ﹤0.01% 6768
2021
Q2 		$1.96M Sell
153,000
-189,500
-55% -$2.04M ﹤0.01% 6674
2021
Q1 		$3.15M Buy
+342,500
New +$2.99M ﹤0.01% 5325

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Citadel Advisors's ZVRA Position: Q1 2026 in Review

Citadel Advisors reduced its Zevra Therapeutics (ZVRA) stake by 26% in Q1 2026, selling an estimated $1.95M and leaving 626,699 shares worth $5.84M. The position accounts for ﹤0.01% of the portfolio, ranked #4088.

Citadel Advisors first reported a position in ZVRA in Q4 2019 and has held it in 19 quarters since. The position peaked at $7.55M in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Citadel Advisors held 626,699 shares of Zevra Therapeutics worth $5.84M as of Q1 2026.
  • Citadel Advisors sold 216,155 Zevra Therapeutics shares in Q1 2026, an estimated $1.95M.
  • Zevra Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4088 holding.
  • Citadel Advisors first reported a position in Zevra Therapeutics in Q4 2019 and has held it in 19 quarters since.
  • Citadel Advisors's Zevra Therapeutics position peaked at $7.55M in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.